Alteration of morphine withdrawal to naloxone by interferon.
The opiate abstinence syndrome represents a fundamental feature of the addictive process. The present study demonstrated that: 1) recombinant leukocyte A Interferon (alpha-IFN) injection prior to chronic morphine treatment reduces addiction liability; and 2) alpha-IFN and not human gamma-IFN injection to morphine dependent rats significantly modifies the naloxone-induced abstinence syndrome in a characteristic dose response manner. Two hypotheses concerning IFN's action were discussed.
D000818:Animals; D005106:Exploratory Behavior / Q000187:drug effects*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D008297:Male; D009020:Morphine / Q000633:toxicity*; D009021:Morphine Dependence / Q000503:physiopathology*; D009270:Naloxone / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013239:Stereotyped Behavior / Q000187:drug effects*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D007370:Interferon Type I; D009270:Naloxone; D009020:Morphine; D007371:Interferon-gamma